NFL shows silent relapses in PPMS cases
NFL shows silent relapses in PPMS cases
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
https://nn.neurology.org/content/7/6/e880
Abstract
Objective
To evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in patients with MS.
Methods
This was an observational cohort study of patients with MS who had a CSF NfL measurement between December 2015 and July 2018 as part of their routine clinical care. Treatment strategies were classified as “No Treatment/No Escalation” (no treatment or no escalation of treatment) or “Treatment/Escalation” (first-line injectable/oral disease-modifying therapies (DMTs), highly active DMTs, or treatment escalation). Change in Expanded Disability Status Scale (EDSS) scores was evaluated after 1-year follow-up.
Results
Of 203 patients with MS, 117 (58%) had relapsing-remitting MS. Disease activity was most frequently indicated by elevated CSF NfL (n = 85), followed by clinical (n = 81) and MRI activity (n = 65). CSF NfL measurements were independently associated with clinical (p = 0.02) and MRI activity (p < 0.001). Of those with elevated CSF NfL as the only evidence of disease activity (n = 22), 77% had progressive MS (PMS). In patients with PMS, 17 (20%) had elevated CSF NfL as the sole indicator of disease activity. Elevated CSF NfL resulted more frequently in Treatment/Escalation than normal CSF NfL (p < 0.001). Median EDSS change at follow-up was similar between patients receiving No Treatment/No Escalation and Treatment/Escalation decisions (p = 0.81).
Conclusions
CSF NfL measurements informed treatment strategies, alongside clinical and MRI measures. CSF NfL levels were the only indicator of disease activity in a subset of patients, which was more pronounced in patients with PMS. Elevated CSF NfL was associated with more Treatment/Escalation strategies, which had an impact on EDSS outcomes at 1 year.
-
- Similar Topics
- Replies
- Views
- Last post
-
-
MRZR+ MS cases are different from others
by frodo » Mon Aug 26, 2019 5:08 am » in MS Etiology and Pathogenesis - 1 Replies
- 745 Views
-
Last post by frodo
Fri Nov 29, 2019 5:59 am
-
-
-
10% of MS cases are due to anti-Neurofascin autoantibody
by frodo » Sun Apr 14, 2019 10:40 am » in General Discussion - 0 Replies
- 469 Views
-
Last post by frodo
Sun Apr 14, 2019 10:40 am
-
-
-
Paediatric MS cases reclassified as MOG‐Ab‐demyelination
by frodo » Mon Apr 08, 2019 4:32 am » in General Discussion - 0 Replies
- 408 Views
-
Last post by frodo
Mon Apr 08, 2019 4:32 am
-
-
-
Up to 10% of MS cases are due to anti-Neurofascin autoantibody
by frodo » Sun Apr 14, 2019 10:18 am » in MS Etiology and Pathogenesis - 0 Replies
- 436 Views
-
Last post by frodo
Sun Apr 14, 2019 10:18 am
-
-
-
Ketogenic diet good for SPMS (at least some cases)
by frodo » Mon Aug 26, 2019 12:05 am » in General Discussion - 0 Replies
- 612 Views
-
Last post by frodo
Mon Aug 26, 2019 12:05 am
-
-
-
Around 13% of MS cases are of genetic origin. 12 pathogenic variants.
by frodo » Tue Aug 13, 2019 7:38 am » in MS Etiology and Pathogenesis - 1 Replies
- 725 Views
-
Last post by frodo
Fri Aug 16, 2019 10:15 am
-
-
- 0 Replies
- 246 Views
-
Last post by frodo
Tue Jul 21, 2020 1:33 am
-
-
Siponimod reduces progression with or without relapses
by frodo » Mon Jul 13, 2020 8:12 am » in MS Etiology and Pathogenesis - 0 Replies
- 244 Views
-
Last post by frodo
Mon Jul 13, 2020 8:12 am
-
-
-
Retinal damage reflects MS progression, not relapses
by frodo » Tue Nov 03, 2020 6:07 am » in MS Etiology and Pathogenesis - 0 Replies
- 208 Views
-
Last post by frodo
Tue Nov 03, 2020 6:07 am
-